Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

A Double-Blind Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 in Subjects Who Completed Either the LIPO-202-CL-18 or LIPO-202-CL-19 Study

LIPO-202-CL-23 is a follow-on study to evaluate the post-treatment safety and duration of clinical effect of LIPO-202 in subjects that completed either the LIPO-202-CL-18 (NCT02397499) or LIPO-202-CL-19 (NCT02398188). No risks related to treatment are anticipated as subjects will not receive additional treatment with LIPO-202 or Placebo for LIPO-202 in this follow-on study.

Inclusion Criteria:

• Healthy male or non-pregnant female subjects who completed Study LIPO-202-CL-18 or LIPO-202-CL-19
• Capable of providing written consent
• Willing to comply with the study procedures and schedule

Exclusion Criteria:

• Female subjects who are pregnant or are not using adequate birth control methods
• Plan on starting a weight loss or exercise program during the study
• Plan to enroll in another investigational drug or device study
• Unlikely or unable to adhere to the study visit schedule